Pacira Pharmaceuticals Inc recalls Zilretta (triamcinolone acetonide extended-release injectable suspension)
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- Failed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months 2-8¿C followed by 6 weeks at 25¿C
- Products
-
- Zilretta (triamcinolone acetonide extended-release injectable suspension)
- Company
- Pacira Pharmaceuticals Inc
- Where it was sold
-
US Nationwide.
Nationwide
- Units affected
- 40,517 kits
- About this recall
- Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: Pacira Pharmaceuticals Inc., San Diego, CA 92121, NDC 65250-003-01 (carton) NDC 65250-001-01 (vial) with Diluent 5 mL Sterile single-use vial, Rx Only, Mfd. for: Pacira Pharmaceuticals, Inc. NDC 65250-002-01